Management of Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Oncologic Patients—A New Promise? Preliminary Results
Ron Batash, Noam Asna, Syed Ahsan Ali, Tatiana Charkovsky, Murad Asali, Sharon Pelles, Moshe Schaffer
Cancers October 15, 2025 DOI: 10.3390/cancers17203321 via OpenAlex
Summary
AI-generated from the abstractA topical combination of amitriptyline and ketamine at new concentrations appears to provide safe and effective relief from chemotherapy-induced peripheral neuropathy (CIPN). This first clinical evaluation suggests the formulation is a promising symptomatic treatment, though larger randomized controlled trials and further study of transdermal delivery systems are needed to confirm the results and improve outcomes.
Study at a glance
| Characteristics | Clinical trial Randomized Peer reviewed |
|---|---|
| Population | Patients with chemotherapy-induced peripheral neuropathy |
| Topics | Ketamine |
| Keywords | Medicine Amitriptyline Peripheral neuropathy Transdermal |
| Citations | 2 |
| Key finding | A topical combination of amitriptyline and ketamine at new concentrations appears safe and effective for symptomatic relief of CIPN. |
Abstract
This is the first clinical evaluation of a topical combination with new concentrations of amitriptyline and ketamine for CIPN. The results suggest this formulation offers a safe and effective option for symptomatic relief. Larger randomized controlled trials and exploration of transdermal delivery systems are warranted to validate these findings and optimize treatment outcomes.